These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 29102270)

  • 1. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
    Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA; Onuigbo NT
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?
    Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2020; 40(1):38-45. PubMed ID: 31196659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
    Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Classical nephroprotection: Renin angiotensin aldosterone system inhibitors].
    Egocheaga MI; Drak Y; Otero V
    Semergen; 2023 Jun; 49 Suppl 1():102018. PubMed ID: 37355297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
    Fernández-Juárez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Lahera V; Casas L; Oliva J;
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1870-6. PubMed ID: 24135218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA; Gariani K; Martin PY
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients.
    Vejakama P; Ingsathit A; McKay GJ; Maxwell AP; McEvoy M; Attia J; Thakkinstian A
    BMC Nephrol; 2017 Nov; 18(1):342. PubMed ID: 29187194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.
    Susantitaphong P; Sewaralthahab K; Balk EM; Eiam-ong S; Madias NE; Jaber BL
    Am J Hypertens; 2013 Mar; 26(3):424-41. PubMed ID: 23382494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
    Feng YH; Fu P
    Chin Med J (Engl); 2016 Jan; 129(1):81-7. PubMed ID: 26712437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early intensive treatment improves outcomes in patients with glomerular hyperfiltration and type 2 diabetes.
    Troya MI; Bonet J; Salinas I; Torres F; Bonal J; Sanmartí A; Romero R
    Med Clin (Barc); 2016 Jan; 146(2):55-60. PubMed ID: 26343155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
    Li SM; He WB; Chen J; Cai QQ; Huang FF; Zhang K; Wang JF; Liu X; Huang H
    Atherosclerosis; 2018 Feb; 269():35-41. PubMed ID: 29258005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report.
    Weir MR; Lakkis JI; Jaar B; Rocco MV; Choi MJ; Kramer HJ; Ku E
    Am J Kidney Dis; 2018 Dec; 72(6):873-884. PubMed ID: 30201547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor blockers: RAAS blockade and renoprotection.
    Ruilope LM
    Curr Med Res Opin; 2008 May; 24(5):1285-93. PubMed ID: 18366863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of RAAS blockade on the progression of diabetic nephropathy.
    Roscioni SS; Heerspink HJ; de Zeeuw D
    Nat Rev Nephrol; 2014 Feb; 10(2):77-87. PubMed ID: 24296623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S; López-Mesa M; Gómez-Fernández P
    Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin-aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial.
    García-Prieto AM; Verdalles Ú; de José AP; Arroyo D; Aragoncillo I; Barbieri D; Camacho RE; Goicoechea M
    Hipertens Riesgo Vasc; 2024; 41(2):95-103. PubMed ID: 38508877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.